全科医学临床与教育
全科醫學臨床與教育
전과의학림상여교육
CLINICAL EDUCATION OF GENERAL PRACTICE
2014年
4期
386-388
,共3页
肺部恶性肿瘤%晚期非小细胞肺癌%转移性肺癌%射频消融
肺部噁性腫瘤%晚期非小細胞肺癌%轉移性肺癌%射頻消融
폐부악성종류%만기비소세포폐암%전이성폐암%사빈소융
lung tumor%primary advanced NSCLC%metastatic lung tumor%radiofrequency ablation
目的观察射频消融术（RFA）治疗肺部恶性肿瘤的临床疗效和安全性。方法对25例肺部肿瘤患者的31个肿瘤行局麻下CT引导经皮射频消融术，术后通过影像学、生存质量、并发症、疾病进展时间等方面评价RFA的治疗价值。结果31个肿瘤均顺利完成了射频消融热毁损肿瘤，其中3个肿瘤进行了2次重叠消融，3例患者失访。31个肿瘤经治疗后病灶完全毁损率达71.43％。完全毁损病灶治疗后6个月内未见复发；而部分毁损病灶治疗后1个月复发率为87.50％，3个月后复发率达到了100％，需行二次射频治疗。胸痛、发热、咳嗽咳痰是患者术后的主要并发症，且均在可耐受范围。患者治疗后各项生存质量评分均有明显变化（t分别=11.43、-4.06、-8.72、-10.89、-3.72、-8.97，P均＜0.05）。病灶完全毁损和病灶部分毁损患者的无进展生存期比较，差异有统计学意义（t=2.10，P＜0.05）。所有患者的1年生存率为60.00％，2年生存率为40.00％。结论射频消融治疗肺部恶性肿瘤近期疗效确切、安全，不良反应能耐受，可明显提高肺癌患者的生存质量。
目的觀察射頻消融術（RFA）治療肺部噁性腫瘤的臨床療效和安全性。方法對25例肺部腫瘤患者的31箇腫瘤行跼痳下CT引導經皮射頻消融術，術後通過影像學、生存質量、併髮癥、疾病進展時間等方麵評價RFA的治療價值。結果31箇腫瘤均順利完成瞭射頻消融熱燬損腫瘤，其中3箇腫瘤進行瞭2次重疊消融，3例患者失訪。31箇腫瘤經治療後病竈完全燬損率達71.43％。完全燬損病竈治療後6箇月內未見複髮；而部分燬損病竈治療後1箇月複髮率為87.50％，3箇月後複髮率達到瞭100％，需行二次射頻治療。胸痛、髮熱、咳嗽咳痰是患者術後的主要併髮癥，且均在可耐受範圍。患者治療後各項生存質量評分均有明顯變化（t分彆=11.43、-4.06、-8.72、-10.89、-3.72、-8.97，P均＜0.05）。病竈完全燬損和病竈部分燬損患者的無進展生存期比較，差異有統計學意義（t=2.10，P＜0.05）。所有患者的1年生存率為60.00％，2年生存率為40.00％。結論射頻消融治療肺部噁性腫瘤近期療效確切、安全，不良反應能耐受，可明顯提高肺癌患者的生存質量。
목적관찰사빈소융술（RFA）치료폐부악성종류적림상료효화안전성。방법대25례폐부종류환자적31개종류행국마하CT인도경피사빈소융술，술후통과영상학、생존질량、병발증、질병진전시간등방면평개RFA적치료개치。결과31개종류균순리완성료사빈소융열훼손종류，기중3개종류진행료2차중첩소융，3례환자실방。31개종류경치료후병조완전훼손솔체71.43％。완전훼손병조치료후6개월내미견복발；이부분훼손병조치료후1개월복발솔위87.50％，3개월후복발솔체도료100％，수행이차사빈치료。흉통、발열、해수해담시환자술후적주요병발증，차균재가내수범위。환자치료후각항생존질량평분균유명현변화（t분별=11.43、-4.06、-8.72、-10.89、-3.72、-8.97，P균＜0.05）。병조완전훼손화병조부분훼손환자적무진전생존기비교，차이유통계학의의（t=2.10，P＜0.05）。소유환자적1년생존솔위60.00％，2년생존솔위40.00％。결론사빈소융치료폐부악성종류근기료효학절、안전，불량반응능내수，가명현제고폐암환자적생존질량。
Objective To observe the clinical efficacy and safety of radiofrequency ablation (RFA) for treating patients with lung cancer. Methods Thirty-one lesions in 25 patients with lung tumor which were non-small cell lung cancer (NSCLC) and metastatic lung tumor were underwent percutaneous adiofrequency ablation.It can evaluate the therapeutic value of the RFA postoperative through the images, quality of life, complications and disease progression time. Results All lesions were taken RFA successfully. Three lesions were taken overlapping ablations for two times and three patients were lost follow-up.The total complete ablation rate was 71.43%in 31 lesions. Completely ablation lesions did not recurred at 6 months after treatment and portion ablation lesions recurrence rate was 87.5% at 1 month after treatment while 100%at 3 months after treatment. The Chest pain, fever, cough were the major complications which were all in tolerance. The scoring of quality of survival in patients with lung cancer after treatment were significantly improved (t=11.43, -4.06, -8.72, -10.89, -3.72, -8.97, P<0.05). The progression-free-survival of completely ablation lesions was significantly higher than portion ablation lesions (t=2.10,P<0.05). One year survival rate was 60.00% and 2 years survival rate was 40.00%. Conclusion Using RFA to treat NSCLC and metastatic lung tumors is efficacious and safe.The adverse reactions were tolerated. It can obviously improve the quality of survival of patients with lung cancer.
